Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Open Forum Infectious Diseases|November 23, 2018
Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and RacePriya Bhagwat, Ighovwerha Ofotokun, Grace A McComsey, et al.
Free Radical Biology & Medicine|June 7, 2008
Accumulation of M1dG DNA adducts after chronic exposure to PCBs, but not from acute exposure to polychlorinated aromatic hydrocarbonsYo-Chan Jeong, Nigel J Walker, Deborah E Burgin, et al.
AIDS Research and Human Retroviruses|July 7, 2020
Short Communication: Impact of Fat Changes on the Effect of Protease Inhibitors on Lumbar Spine Bone Mineral Density Changes with Antiretroviral Therapy InitiationJoshua Garza, Carlee Moser, Douglas W Kitch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2021
Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260sJohn R Koethe, Carlee Moser, Todd T Brown, et al.
Open Forum Infectious Diseases|October 6, 2016
Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260sSahera Dirajlal-Fargo, Carlee Moser, Todd T Brown, et al.
The Journal of Clinical Endocrinology and Metabolism|July 23, 2019
CT Fat Density Accurately Reflects Histologic Fat Quality in Adults With HIV On and Off Antiretroviral TherapyJordan E Lake, Carlee Moser, Liz Johnston, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 24, 2018
Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral TherapyVanessa El Kamari, Carlee Moser, Corrilynn O Hileman, et al.
Plos One|September 7, 2021
Associations of circulating dimethylarginines with the metabolic syndrome in the Framingham Offspring studyIbrahim Musa Yola, Carlee Moser, Meredith S Duncan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 23, 2016
Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260sGrace A McComsey, Carlee Moser, Judith Currier, et al.
Open Forum Infectious Diseases|November 19, 2019
Changes in the Fungal Marker β-D-Glucan After Antiretroviral Therapy and Association With AdipositySahera Dirajlal-Fargo, Carlee Moser, Katherine Rodriguez, et al.
Pageof 9